Drug Profile
Sodium cromoglicate inhalant - Respivant Sciences
Alternative Names: Cromolyn sodium - Patara Pharma; Disodium cromoglicate; PA-101; PA-101B; RVT-1601; Sodium cromoglicate inhalant - Patara PharmaLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Patara Pharma
- Developer Patara Pharma; Respivant Sciences
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antitussives; Benzopyrans; Chromones; Nootropics; Small molecules
- Mechanism of Action Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pruritus; Systemic mastocytosis
- No development reported Cough; Respiratory tract disorders
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Respiratory-tract-disorders(In neonates) in USA (Inhalation, Aerosol)
- 28 Sep 2022 No development reported - Phase-II for Cough in United Kingdom, Netherlands, USA, Australia, Belgium, Canada, Czech Republic, Germany, Italy, New Zealand, Turkey (Inhalation)
- 11 Jun 2020 Respivant Sciences terminates the phase IIb SCENIC trial in Cough in Australia, Belgium, Canada, Czech Republic, Germany, Italy, New Zealand, Turkey, Netherlands and United Kingdom due to COVID-19 pandemic (Inhalation) (NCT03864328)